menu
    • menu
    [{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Acerus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Divestment","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Agreement","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Cypionate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Acerus Pharmaceuticals

    Menu

    Acerus Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Recipient : University of Utah

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Natesto Testosterone Nasal Gel for Hypogonadal Men

                            Details : Natesto is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Erectile Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            August 02, 2022

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Recipient : University of Utah

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desmopressin Acetate

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Acerus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to No...

                            Details : Noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. It is the first FDA-approved therapy for nocturia.

                            Product Name : Noctiva

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            March 09, 2022

                            Lead Product(s) : Desmopressin Acetate

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Acerus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desmopressin Acetate

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Recipient : Serenity LLC

                            Deal Size : $16.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Acerus Announces Definitive Agreement to Acquire Serenity LLC and The Global Rights To NOCTIVA™

                            Details : Both Noctiva™ and Natesto® are highly clinically differentiated products with significant patent protection into the 2030s, that Acerus management feels could reach double-digit market share in each of these large market opportunities.

                            Product Name : Noctiva

                            Product Type : Hormone

                            Upfront Cash : $6.0 million

                            February 28, 2022

                            Lead Product(s) : Desmopressin Acetate

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Recipient : Serenity LLC

                            Deal Size : $16.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : Verity Pharmaceuticals Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO...

                            Details : Under the terms of the agreement, Verity Pharma will promote NATESTO across the island of Puerto Rico, leveraging its existing commercial footprint and health care network. Acerus will maintain control of distribution, market access, and regulatory activ...

                            Product Name : Natesto

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            January 10, 2022

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : Verity Pharmaceuticals Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

                            Details : Testosterone is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypogonadism.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            July 26, 2021

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : Amneal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO®

                            Details : Under the terms of the agreement, Amneal will sell NATESTO, Testosterone Nasal gel to the company’s existing Endocrinology targets through June 30, 2024.

                            Product Name : Natesto

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            May 10, 2021

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : Amneal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : Aytu BioPharma

                            Deal Size : $7.5 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma

                            Details : Acerus will acquire all remaining rights to Natesto in the United States from Aytu. Acerus will assume all product responsibilities associated with Natesto.

                            Product Name : Natesto

                            Product Type : Hormone

                            Upfront Cash : $7.5 million

                            April 01, 2021

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : Aytu BioPharma

                            Deal Size : $7.5 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Acerus Pharmaceuticals

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone Cypionate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Recipient : University of Miami

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections

                            Details : Testosterone Cypionate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Eunuchism.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 19, 2020

                            Lead Product(s) : Testosterone Cypionate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Recipient : University of Miami

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth